1. Introduction {#sec1-ijms-20-02279}
===============

Long non-coding RNAs (lncRNAs) represent a large class of transcribed RNA molecules with a length of more than 200 nucleotides. Like other protein coding genes, they are probably transcribed by RNA polymerase II (RNA pol II), and are polyadenylated \[[@B1-ijms-20-02279]\]. Generally, expression levels of lncRNAs appear to be lower than protein-coding genes \[[@B2-ijms-20-02279]\] and specific to the tissues \[[@B3-ijms-20-02279]\]. Although the function of most of the lncRNAs is unknown, an increasing number of them have been functionally characterized. LncRNAs have been involved in many biological activities such as; (i) the regulation of mRNA processing; (ii) the regulation of transcription, functioning as *cis*- and *trans*-acting modulators of protein-coding gene expression; (iii) the modulation of post-transcriptional control; (iv) the regulation of protein activity; (v) the production of scaffolds for higher-order complexes, such as Polycomb repressive complex 2 (PRC2) \[[@B4-ijms-20-02279]\]. LncRNAs also represent an emerging class of tumor biomarkers being widely documented as to their deregulation in cancer development and progression \[[@B5-ijms-20-02279]\].

Although most of the studies in the literature have shown the role of lncRNAs in tumor cells, a series of recent experimental evidences have suggested investigating their role in tumor microenvironment (TME) \[[@B6-ijms-20-02279]\]. LncRNAs, as well as small noncoding RNAs, are transported in the circulation by extracellular vesicles, mainly exosomes \[[@B7-ijms-20-02279]\]. These play a fundamental role in the interaction between cancer cells and the surrounding environment during tumor progression \[[@B8-ijms-20-02279]\]. In fact, exosomal shuttle RNAs (exRNAs) might be used as a signal to change gene expression patterns in the recipient cell of TME \[[@B9-ijms-20-02279],[@B10-ijms-20-02279]\]. Emerging data suggested that, during tumor disease progression, lncRNAs are involved in tumor-stroma signaling, regulating the phenotype of cancer-associated stromal cells. Stromal lncRNAs are able to induce the release of several chemokines enhancing the metastatic potential of tumor cells \[[@B11-ijms-20-02279]\]. LncRNAs can also influence cancer stem cells (CSC) phenotype and differentiation status within the TME promoting tumor growth, invasion and metastatic progression \[[@B12-ijms-20-02279]\]. In addition, some studies have shown than lncRNAs may be involved both in mechanisms of communication between metastatic cancer cells and extracellular matrix (ECM) and in ECM turnover \[[@B13-ijms-20-02279]\].

Many lncRNAs are also expressed in immune cells, and appear to play critical roles in the regulation of immune response \[[@B14-ijms-20-02279]\]. In animal models, lncRNAs are implicated in T cell activation/differentiation \[[@B15-ijms-20-02279]\], and are able to modulate cytotoxicity CD8^+^ T cells recruitment within the TME, promoting metastatic disease. \[[@B16-ijms-20-02279]\].

LncRNA *HOTAIR* (HOX Transcript Antisense Intergenic RNA) located on chr.12q13.13 (between *HOXC11* and *HOXC12*) \[[@B17-ijms-20-02279]\] acts as a regulator of chromatin states by binding, with its 5′end, the PRC2. With this mechanism *HOTAIR* can guide PRC2 to target genes related with tumor metastasis in breast cancer \[[@B18-ijms-20-02279]\]. *HOTAIR* further interacts with the methyltransferase specific to histone 3 lysine 27, Enhancer of Zeste homolog 2 (EZH2), and lysine-specific demethylase 1 (LSD1), a central player in epigenetic regulation, through its 5′ end and 3′ end, respectively. Through this mechanism, *HOTAIR* can function as a scaffold directing these proteins to co-occupy the same genomic regions \[[@B19-ijms-20-02279]\]. The same scaffold is able to link E3 ubiquitin ligases with their substrates to accelerate proteolysis \[[@B20-ijms-20-02279]\]. A recent study showed that *HOTAIR* can inhibit Androgen Receptor (AR) ubiquitination, preventing AR protein degradation, and increasing AR protein stability. In fact, *HOTAIR* is able to bind the N-Terminal Domain (NTD) of the AR protein blocking recruitment of the E3 ubiquitin ligase MDM2 that interacts with AR through the same domain \[[@B21-ijms-20-02279]\].

Summing up the experimental evidences, *HOTAIR* is able to: (i) promote the epigenetic activation/repression of gene expression; (ii) affect the target suppression of gene expression through competitive binding to miRNAs; (iii) modify gene expression, at post-transcriptional level, interacting with transcription factors and ribosomes or binding to splicing factors \[[@B22-ijms-20-02279]\].

Aberrant *HOTAIR* expression has been detected in several human cancers showing a fundamental role in tumor proliferation, angiogenesis, progression, drug resistance and worse prognosis \[[@B23-ijms-20-02279]\]. In addition, numerous experimental evidences have focused the attention on the potential role of *HOTAIR* as a circulating marker and therapeutic target for cancer patients \[[@B24-ijms-20-02279]\].

This review aimed to highlight the potential role of *HOTAIR* in the modulation of TME, focusing attention in particular on its relation with cellular components of TME and ECM proteins. *HOTAIR*, through interaction with microenvironment elements, could play a main role in the activation of specific growth and invasion molecular pathways, and in the regulation of immune response during tumor progression.

2. Tumor Microenvironment Cells {#sec2-ijms-20-02279}
===============================

The tumor microenvironment consists of different cellular and non-cellular secreted components. Cellular components include cancer-associated fibroblasts (CAF), endothelial cells, immune cells (T-cells, tumor associated macrophages (TAM), dendritic cells, mast cells etc.) and cancer stem cells (CSC) \[[@B25-ijms-20-02279]\]. Secreted non cellular components comprise cytokines, growth factors, metabolites and extracellular matrix (ECM) proteins \[[@B26-ijms-20-02279]\]. All TME elements play fundamental roles in tumor growth and progression \[[@B25-ijms-20-02279]\].

2.1. HOTAIR and Cancer-Associated Fibroblasts {#sec2dot1-ijms-20-02279}
---------------------------------------------

Fibroblasts, the predominant stromal cell type in the TME, are activated by tumor cells into cancer-associated fibroblasts (CAFs) through the secretion of paracrine growth factors, cytokines, and ECM proteins \[[@B26-ijms-20-02279]\]. CAFs are important mediators of tumor-stroma communication, and are able, directly or indirectly, to promote different biological processes, such as proliferation, invasion, angiogenesis and drug resistance \[[@B27-ijms-20-02279]\].

Although the role of lncRNAs in CAF modulation is poorly investigated, some studies suggested that they can contribute to: i) CAFs phenotype and function; ii) induction of epithelial-mesenchymal transition (EMT) in tumor cells, mainly promoting TGF-β signaling \[[@B28-ijms-20-02279]\].

A recent study highlighted that breast cancer (BC) cell lines (Estrogen positive (ER+) and Triple Negative (TNBC)), grown in CAFs conditioned media (CAF-CM) lead the production of abundant levels of TGF-B1 cytokine inducing EMT of BC cells. To analyze the epigenetic mechanism by which CAFs induce EMT, several lncRNAs have been measured in BC cell lines revealing the up-regulation of *HOTAIR* in CAF-CM.

In addition, knock-down of *HOTAIR* in cancer cells is able to induce E-cadherin expression and vimentin and beta-catenin repression, suggesting that CAFs promote EMT and metastasis by activating *HOTAIR* expression. Knockdown of *HOTAIR* in orthotropic mice is able to attenuate the metastatic potential of tumor cells, blocking the crosstalk between CAFs and cancer cells \[[@B29-ijms-20-02279]\]. However, the mechanisms by which CAFs activate *HOTAIR* remain to be addressed. TGF-β is able to assemble a receptor complex that activates Smad proteins (SMAD2, SMAD3 and SMAD4) regulating transcription \[[@B30-ijms-20-02279]\]. In CAF-CM of BC cells, high levels of phosphorylated Smads proteins have been detected. The induced repression of these proteins leads to a 50--60% reduction in *HOTAIR* expression. CAFs could be able to stimulate the direct binding of SMAD2, 3, and 4 to the promoter region of *HOTAIR* inducing its transactivation \[[@B29-ijms-20-02279]\]. In addition, since the activation of CDK5 is essential for CAF-induced EMT, Ren and collaborators also demonstrated that CAFs mediate *HOTAIR* expression and EMT by targeting CDK5 signaling \[[@B29-ijms-20-02279]\]. These observations suggest a novel epigenetic mechanism by which CAFs would modulate EMT and tumor progression by TGF-ß1/CDK5/*HOTAIR* axis.

2.2. HOTAIR and Endothelial Cells {#sec2dot2-ijms-20-02279}
---------------------------------

TME endothelial cells are responsible for supporting tumor neovasculature, also participating in several molecular signaling pathways. In fact, tumor-associated endothelial cells display high TGF-beta1 and CD105 expression involved in promoting angiogenesis \[[@B31-ijms-20-02279]\].

Several lncRNAs are described as able to directly or indirectly modulate neo-angiogenesis in TME \[[@B32-ijms-20-02279]\], but between these, *HOTAIR* appears to have a fundamental role in the promotion of angiogenesis during tumor progression. In nasopharyngeal carcinoma (NPC) *HOTAIR* is strongly up-regulated in cell lines and tissues, and its knockdown leads to a significant decrease of several angiogenic factors, such as vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (Ang2) \[[@B33-ijms-20-02279]\]. These data have been also been validated in animal xenograft, suggesting the powerful evidence that silencing of *HOTAIR* can act as an anti-angiogenesis agent to NPC carcinogenesis. *HOTAIR* is directly involved in the promotion of VEGFA transcription. In fact, the results of luciferase assays revealed that HOTAR activated the transcription of 2.3 kb *VEGFA* promoter. Moreover, a functional proteomic profiling identified 14 proteins up-regulated and 29 proteins down-regulated by *HOTAIR* silencing in NPC cells. Between these, Glucose regulated protein 78 (*GRP78*), belonging to the heat shock protein 70 (HSP70) family \[[@B34-ijms-20-02279]\], has been validated as an anti-angiogenetic target of *HOTAIR* in NPC cells \[[@B33-ijms-20-02279]\].

*HOTAIR* is also involved in the angiogenesis modulation of glioma cells. Its downregulation leads to the inhibition of pro-angiogenic activity in in vitro models. Also in this case, the silencing of *HOTAIR* in glioma cells dramatically decreases *VEGFA* expression affecting proliferation, migration and tube formation \[[@B35-ijms-20-02279]\]. Experimental evidences showed that cancer cells are able to secrete extracellular vesicles (EV) to support tumor progression \[[@B36-ijms-20-02279]\]. Numerous lncRNAs, including *HOTAIR*, are found in EVs derived from different cancer cells \[[@B37-ijms-20-02279]\]. Ma and collaborators through RT-PCR analysis confirmed the presence of *HOTAIR* in conditioned medium of glioma cells and experiments using detergents, and RNAse indicated that *HOTAIR* remains stable because it is protected by membranes \[[@B35-ijms-20-02279]\]. These observations suggested that *HOTAIR*, produced by tumor cells, would be able to be released in TME through EVs and transmitted to endothelial cells promoting angiogenesis.

In a non-neoplastic model, a recent study showed that *HOTAIR* is down-regulated in endothelial cells isolated from atherosclerotic plaque in atherosclerosis patients compared with corresponding vascular wall, suggesting that *HOTAIR* plays a protective role for endothelial cells injury \[[@B38-ijms-20-02279]\]. Moreover, serum levels of thymic stromal lymphopoietin (TSLP), belonging to IL-7 like cytokine family, decrease in atherosclerosis patients, and positively correlates with *HOTAIR* expression in endothelial cells. TSLP is able to activate *HOTAIR* transcription through the PI3K/AKT pathway regulating endothelial cells proliferation and migration \[[@B38-ijms-20-02279]\].

2.3. HOTAIR and Cancer Stem Cells {#sec2dot3-ijms-20-02279}
---------------------------------

Cancer stem cells (CSCs) can be a critical component of TME being strongly involved in promoting invasion/metastasis process and drug resistance \[[@B39-ijms-20-02279],[@B40-ijms-20-02279]\]. CSC proliferation can be regulated by many extrinsic factors derived from microenvironment cells. Several studies described that different lncRNAs are able to modulate CSCs proliferation promoting tumor progression \[[@B41-ijms-20-02279]\]. Li et al., showed that *HOTAIR* is able to accelerate liver cancer stem cells proliferation in vitro and *in vivo,* on xenograft mice, through downregulation of the histone methyltransferase SET Domain-Containing Protein 2 (*SETD2*). The *SETD2* gene has been shown to play a tumor suppressor role in human cancer \[[@B42-ijms-20-02279]\]. In fact, cells lacking *SETD2* display microsatellite instability (MSI) and an elevated spontaneous mutation frequency \[[@B43-ijms-20-02279]\]. *HOTAIR* is able to reduce the *SETD2* transcriptional expression through blocking RNApolII catalytic function by dissociating the CREB-P300- RNApolII complex. Therefore, *SETD2* represents a crucial target of *HOTAIR* involved in epigenetic DNA damage repair, abnormal expression of cell cycle-related genes and microsatellite instability (MSI) \[[@B44-ijms-20-02279]\].

*HOTAIR* appears as a key modulator of breast CSCs being strongly upregulated in BC CSCs models. *HOTAIR* is able to modulate proliferation, colony formation, migration and self-renewal capacity by negatively regulating miR34a \[[@B45-ijms-20-02279]\]. The searching of the functional region of *HOTAIR* involved in this regulation showed that the full-length *HOTAIR* sequence is required for its regulatory role. Since miR-34a directly targets the stem cell marker *Sox2*, reducing its protein level \[[@B46-ijms-20-02279]\], its mRNA expression has been also evaluated in BC CSCs. *Sox2* appears strongly upregulated in BC CSCs, highlighting its indirect modulation by *HOTAIR*. In conclusion, *HOTAIR* might play a critical role in maintaining CSC self-renewal capacity by negatively regulating *miR-34a* and, consequently, positively *Sox2* \[[@B45-ijms-20-02279]\]. In non-small cell lung cancer (NSLC) patients, high *HOTAIR* expression is associated with drug resistance. In in vitro models, drug resistance induced by elevated *HOTAIR* expression may be caused by the promotion of tumor sphere cell growth and activation of tumor stem cell biomarkers such as *Nanog, Oct3/4, Sox2, c-Myc, β-catenin*, and *Klf4* \[[@B47-ijms-20-02279]\]. In oral squamous cell carcinoma (OSCC), overexpression of *HOTAIR* is tightly associated with the metastatic features of tumor cells, and is able to enhance cancer stemness. On the contrary, silencing of *HOTAIR* strongly attenuates oncogenic and invasion potential in xenograft nude mice. In addition, *HOTAIR* downregulation leads to the decreased expression of mesenchymal-like markers (vimentin, FN1, Snail, Twist and ZEB1) and increased expression of epithelial protein (E-cadherin) in OCSC cells, highlighting its main role of *HOTAIR* in the modulation of EMT features \[[@B48-ijms-20-02279]\].

The role of *HOTAIR* in the modulation of stem-cell phenotypes has been also investigated in normal conditions. Exosomal *HOTAIR* released from gluteal-femoral fat might be able to promote intestinal cells proliferation, inducing both the stem cell and proliferation markers, such as several Wnt pathway-related genes (*Lgr5, Cyclin d1, cMyc*) \[[@B49-ijms-20-02279]\]. *HOTAIR*, together with *miR-10b*, are involved in the malignant transformation of normal liver stem cells. Induced expression of both ncRNAs leads to the loss of E-cadherin and promotes EMT \[[@B46-ijms-20-02279]\]. In bone marrow derived mesenchymal stem cells (MSCs) the overexpression and knockdown of *HOTAIR* interferes with cell differentiation and modulate senescence-associated changes in gene expression and DNA methylation. Targeting of *HOTAIR* to specific sites in the genome seems to be mediated by triple helix formation \[[@B50-ijms-20-02279]\].

2.4. HOTAIR and Hypoxic Microenvironment {#sec2dot4-ijms-20-02279}
----------------------------------------

One of the most investigated features of TME is hypoxia, defined as a reduction in the normal level of tissue oxygen tension \[[@B51-ijms-20-02279]\]. The hypoxic TME is involved in many oncogenic mechanisms, such as decreased DNA repair, increased mutation rate and chromosomal instability \[[@B52-ijms-20-02279]\], cell proliferation signaling \[[@B51-ijms-20-02279]\], invasion and metastasis \[[@B53-ijms-20-02279]\], angiogenesis \[[@B54-ijms-20-02279]\], inflammation and immunity \[[@B55-ijms-20-02279]\] and reduced sensitivity to radiotherapy, chemotherapy and immunotherapy \[[@B56-ijms-20-02279]\].

Several experimental evidences highlighted an increased production of exosomes in response to hypoxia \[[@B57-ijms-20-02279],[@B58-ijms-20-02279]\] and oxidative stress \[[@B59-ijms-20-02279]\]. In addition, many studies have demonstrated the aberrant expression of several non-coding RNAs under hypoxic condition.

Both microRNA and lncRNA in hypoxic microenvironment are able to drive the selection of a stem-like and more aggressive cancer cell population \[[@B60-ijms-20-02279],[@B61-ijms-20-02279]\]. In particular, hypoxia-responsive lncRNAs (HRLs) play crucial roles in regulating hypoxic gene expression by acting as effectors of the indirect response to the transcription factor HIF (hypoxia-inducible factor) or direct modulators of the HIF-transcriptional cascade \[[@B62-ijms-20-02279]\].

Different studies describe the role of *HOTAIR* in the hypoxic microenvironment of human cancers. *HOTAIR* is upregulated by hypoxia in NSCLC cells, and it is able to directly interact with HIF-1α through putative hypoxia-responsive elements (HREs) in the promoter region. The binding of *HIF-1α* to the *HOTAIR* promoter in vivo lead the increase of cancer cell proliferation, migration, and invasion \[[@B63-ijms-20-02279]\]. In renal cell carcinoma (Rcc) *HOTAIR* is able to promote tumor progression through inhibition of *miR-217* expression, and modulating the expression of *HIF-1*α and *AXL* receptor tyrosine kinase. In addition, *HOTAIR* knockdown significantly suppresses tumor growth and ki-67 expression, increases *miR-217* levels and decreases the expression of *HIF-1*α and *AXL*, inhibiting tumor growth and EMT \[[@B64-ijms-20-02279]\]. More recent studies showed that *HOTAIR* can be transcriptionally induced upon hypoxic conditions also in other tumor types, including colon cancer, breast cancer, cervical cancer, and neuroblastoma cells \[[@B65-ijms-20-02279]\]. While *HOTAIR* expression is induced upon hypoxia, several *HOTAIR* target genes and tumor suppressors such as *HOXD10, HOXD8, PCDHGA8,* and *PCDHB5* are down-regulated under hypoxic conditions. This mechanism of silencing could be related to the *HOTAIR* recruitment of PRC2 and LSD1 complexes which introduce H3K27-trimethylation and H3K4-demethylation respectively at the above target gene promoters \[[@B65-ijms-20-02279]\]. Through its interaction with *HIF-1a*, *HOTAIR* is also able to induce radio-resistance in cervical cancer cells, suggesting that *HOTAIR*-HIF-1α axis might be a crucial mechanism for radio-resistance modulation hypoxia-induced \[[@B66-ijms-20-02279]\].

2.5. HOTAIR and Immune Cells {#sec2dot5-ijms-20-02279}
----------------------------

Immune cells represent the most abundant cellular component within TME. In particular, T-cells account for about 50% of intratumoral cells playing a main role in influencing antitumor immunity in both positive and negative ways, depending upon the cell type \[[@B67-ijms-20-02279]\].

Tumor-associated macrophages (TAM) cells play a fundamental role in the inhibition of antitumor immunity by secreting suppressive cytokines, leading to an increase of angiogenic process and promoting tumor growth \[[@B68-ijms-20-02279]\]. At same manner, an increased presence of myeloid-derived suppressor cells (MDSC) are strongly associated with tumor progression and poorer outcome \[[@B69-ijms-20-02279]\].

LncRNAs play fundamental roles in immune cell development, lineage differentiation and effector function \[[@B70-ijms-20-02279]\]. However, information on the role of *HOTAIR* in immune cells modulation within TME is limited. Hepatoma cell lines with *HOTAIR* overexpression secreted higher CCL2 and this promotes TAM and MDSCs proliferation. CCL2 is required for TAM and MDSCs recruitment in the tumor microenvironment, suggesting that *HOTAIR* has a main role in the modulation of this process promoting tumor growth and metastasis \[[@B71-ijms-20-02279]\]. The analysis of a correlation between CCL2 and *HOTAIR* expression in Gene Expression Omnibus (GEO) data set of HCC, revealed that patients with high expression levels of both markers are associated with advanced clinical stages, suggesting that *HOTAIR* could be a specific target for immunotherapy against CCL2 \[[@B67-ijms-20-02279]\]. Prostate cancer cells treated with androgen deprivation therapy strongly increase the recruitment of mast cells. In turn, infiltrating mast cells are able to decrease AR transcription through *HOTAIR* activation increasing cell invasion via *MMP* expression induction \[[@B72-ijms-20-02279]\].

We have recently highlighted the aberrant expression of *HOTAIR* in metastatic melanoma patients and shown its high expression in lymphocytes surrounding metastatic tumor cells \[[@B73-ijms-20-02279]\]. In our study we clearly showed the in situ expression of *HOTAIR* on immune cells surface within TME. The images of the staining at higher magnification highlight the details of *HOTAIR* staining on the plasma membrane of lymphocytes ([Figure 1](#ijms-20-02279-f001){ref-type="fig"} (source: ref 74)). *HOTAIR* expression would appear to be associated with specific "vesicle-like" membrane projections.

However, it is not clear whether the presence of *HOTAIR* on intra-tumor lymphocytes of patients with metastatic melanoma is associated with endogenous production of the lncRNA, or it is the result of a signal transmission between tumor cells and TME cells.

*HOTAIR* expression can be induced in normal immune cells upon treatment with lipopolysaccharide (LPS), an endotoxin able to promote immune and pro-inflammatory response in macrophages. In turn, *HOTAIR* is able to promote several cytokines and inflammatory genes, such as *IL-6, iNOS, TNFα,* and *MIP-1B*, highlighting its critical role in immune response upon LPS-stimulation. *HOTAIR* is also required for LPS-induced degradation of IκBα (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) and activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) with its nuclear translocation \[[@B74-ijms-20-02279]\]. It is known that NF-κB activation in immune cells enhances inflammation in the TME by increasing the secretion of pro-inflammatory cytokines such as TNF-α and IL-6, and promotes the rapid tumor cells proliferation \[[@B75-ijms-20-02279]\].

2.6. HOTAIR and Extracellular Matrix {#sec2dot6-ijms-20-02279}
------------------------------------

Although extracellular matrix constitutes the non-cellular component of TME, it represents a dynamic and versatile structure able to influence fundamental aspects of tumor cell biology \[[@B76-ijms-20-02279]\]. In fact, during cancer progression, overcoming the physical barriers through the interaction with ECM components is a fundamental step of the invasion/metastatic process. Several studies highlighted an important role of lncRNAs in ECM organization and remodeling \[[@B77-ijms-20-02279]\].

*HOTAIR* has an important function in ECM signaling in breast cancer, above all in invasive "claudin low" molecular subtype. BC cells grown in a 3D culture on a substrate enriched in laminin show a significant up-regulation of *HOTAIR* expression. Not all the different isoforms of *HOTAIR* have been characterized, even if the aberrant activation of the promoter region upstream of *HOTAIR*-N has been mainly implied in invasive breast cancer \[[@B78-ijms-20-02279]\]. Li et al. showed that a novel isoform *HOTAIR*-N is activated in 3D culture of Claudin-low BC cells enriched in laminin. *HOTAIR* expression is induced by increased H3K4me3 and BRD4 binding to the novel *HOTAIR*-N promoter in BC cells attached to ECM, suggesting its main role in ECM organization and tumor invasion pathway signaling \[[@B79-ijms-20-02279]\].

The interplay between ECM components and *HOTAIR* has been also demonstrated in lung cancer cells. The enrichment of collagen I in a 3D culture model determines the loss of morphological features of well-differentiated lung adenocarcinoma and the up-regulation of *HOTAIR* expression. On the contrary, the treatment of lung cancer cells with an antibody against collagen I receptor lead to a decrease of *HOTAIR* expression, suggesting that *HOTAIR* expression in tumor tissues is the result of tumor cell response to collagen I, abundantly present in TME \[[@B80-ijms-20-02279]\].

Osteopontin is another component of ECM associated with several biological processes, such as angiogenesis, inflammation, tissues remodeling, but also metastatic progression. In fact, OPN increases pro-MMP2 expression in an NFKb-dependent manner during ECM invasion \[[@B81-ijms-20-02279]\]. OPN is able to induce *HOTAIR* expression in a dose and time-dependent manner in different tumor cell lines, while OPN knockdown decreases *HOTAIR* expression. Activation of the PI3K/AKT pathway seems to be associated with the effect of OPN on the regulation of *HOTAIR*. Moreover, the interferon regulatory factor *IRF1*, a transcriptional regulator of IFN-stimulated genes, might participate in the transcriptional regulation of *HOTAIR*. In fact, promoter activity and ChIP assays confirmed that *IRF1* could bind to the *HOTAIR* promoter and inhibit *HOTAIR* expression \[[@B82-ijms-20-02279]\].

3. Conclusions {#sec3-ijms-20-02279}
==============

Although the role of lncRNAs within TME is still poorly investigated, a number of studies suggest the main contribution of *HOTAIR* in TME intracellular signaling and its important contribution in modulating different molecular pathways involved in tumor phenotype modifications during metastatic progression ([Figure 2](#ijms-20-02279-f002){ref-type="fig"}). The evaluation of *HOTAIR* expression in TME could provide fundamental information, not only for the prognosis, but also for the prediction of the therapeutic response of cancer patients.
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![*HOTAIR* expression in immune cells within tumor microenvironment of a melanoma sample. The red arrows indicate membrane projections in which *HOTAIR* staining is predominantly concentrated (magnification 40×).](ijms-20-02279-g001){#ijms-20-02279-f001}

![Schematic representation of exosomal *HOTAIR* in tumor microenvironment with details of the main molecular pathways associated with cellular and non-cellular components: (i) In CAF cells: TGF-β assembling the receptor complex (TGFbRI-TGFbRII) activates Smad proteins (SMAD2, SMAD3 and SMAD4) that directly bind *HOTAIR* promoter, inducing its transactivation; (ii) In CSC cells: *HOTAIR* leads to (a) the downregulation of the tumor suppressor gene *SETD2*, promoting microsatellite instability, high mutation rate, and interfering with DNA damage repair, (b) the downregulation of *miR34*a with the consequent induction of stem cell marker *Sox2*; (iii) In endothelial cells: *HOTAIR* induces angiogenesis-promoting *VEGFA* transcription and downregulating the anti-angiogenetic marker *GRP78*; (iv) In immune cells: *HOTAIR* is able to induce the degradation of IκBα with the consequent activation of NF-κB pathways and secretion of pro-inflammatory cytokines; (v) ECM proteins: Laminin, Collagen I, Osteopontin are able to induce *HOTAIR* overexpression modulating PI3K/AKT pathways and promoting cell mobility and invasion.](ijms-20-02279-g002){#ijms-20-02279-f002}
